Epigenetic engineering for optimal chimeric antigen receptor T cell therapy

Recent advancements in cancer immunotherapy, such as chimeric antigen receptor (CAR)‐engineered T cell therapy and immune checkpoint therapy, have significantly improved the clinical outcomes of patients with several types of cancer. To broaden its applicability further and induce durable therapeuti...

Descripción completa

Detalles Bibliográficos
Autores principales: Ito, Yusuke, Kagoya, Yuki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Review Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9633293/
https://www.ncbi.nlm.nih.gov/pubmed/36000807
http://dx.doi.org/10.1111/cas.15541

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9633293/
https://www.ncbi.nlm.nih.gov/pubmed/36000807
http://dx.doi.org/10.1111/cas.15541

Ejemplares similares